Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence.

CAR therapy has shown promise in treating cancer, but at the cost of unexpected toxicity against normal tissues, not predicted by preclinical testing. We are working to generate more physiologically relevant models for preclinical CAR toxicity testing, and in doing so, have discovered that CAR therapy induces immunogenic cell death, with the potential for cures.

Duke Scholars

Author John Howard Sampson Neurosurgery